Medmira Inc. Stock
€0.050
Your prediction
Medmira Inc. Stock
Pros and Cons of Medmira Inc. in the next few years
Pros
Cons
Performance of Medmira Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Medmira Inc. | -2.940% | 3.125% | -9.174% | -10.811% | -23.846% | - | - |
Theralase Technologies Inc | -3.400% | -0.500% | -9.545% | -34.967% | -4.327% | -22.266% | -30.662% |
Atossa Genetics Inc | 0.460% | -6.686% | 10.499% | 73.163% | 36.451% | -57.763% | -30.557% |
NetScientific plc | -0.850% | 0.000% | -4.918% | -9.375% | -4.918% | -54.688% | -4.918% |
News
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody
MedMira Announces the Hire of Vice President of Business Development
Halifax, Nova Scotia, 30 April, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the
MedMira gibt Einstellung eines Vizepräsidenten für Geschäftsentwicklung bekannt
Halifax, Nova Scotia, 30 April, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the